Untitled

Daewoong releases trial results for autoimmune disease treatment in US - Rx Management Group

Hanmi to get ￦11.6 billion in royalty if FDA approves Rolontis - Rx Management Group

Medpacto releases trial results at US conference - Rx Management Group

Yuhan, Cyclica to co-develop new drugs - Rx Management Group

Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host Disease - Rx Management Group

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting - Rx Management Group

Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD - Rx Management Group

Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting - Rx Management Group

BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis - Rx Management Group

Alpine Immune Sciences Presents New ALPN-101 Preclinical Data at the 2019 American College of Rheumatology (ACR) Annual Meeting - Rx Management Group

Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors - Rx Management Group

Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome - Rx Management Group

Novartis data show tropifexor (LJN452) significantly improves several key biomarkers of NASH in patients with moderate to severe fibrosis - Rx Management Group